These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 2009893)
1. Exercise tolerance in patients with heart failure--how should it be measured? Cowley AJ; Fullwood L; Stainer K; Hampton JR Eur Heart J; 1991 Jan; 12(1):50-4. PubMed ID: 2009893 [TBL] [Abstract][Full Text] [Related]
2. Effect of flosequinan on exercise capacity and cardiac function in patients with chronic mild heart failure: a double-blind placebo-controlled study. Hori M; Sato H; Ozaki H; Inoue M; Naka M; Fukunami M; Fukushima M; Kunisada K Heart Vessels; 1992; 7(3):133-40. PubMed ID: 1500398 [TBL] [Abstract][Full Text] [Related]
3. A comparison of the effects of captopril and flosequinan in patients with severe heart failure. Cowley AJ; Wynne RD; Swami A; Birkhead J; Skene A; Hampton JR Cardiovasc Drugs Ther; 1992 Oct; 6(5):465-70. PubMed ID: 1450090 [TBL] [Abstract][Full Text] [Related]
4. Long-term evaluation of treatment for chronic heart failure: a 1 year comparative trial of flosequinan and captopril. Cowley AJ; McEntegart DJ; Hampton JR; Barnett DB; Bexton RS; Boyle R; Hanley SP; Millar-Craig M; Morris GK; Nicholls AJ Cardiovasc Drugs Ther; 1994 Dec; 8(6):829-36. PubMed ID: 7742261 [TBL] [Abstract][Full Text] [Related]
5. The effects of flosequinan on submaximal exercise in patients with chronic cardiac failure. Elborn JS; Riley M; Stanford CF; Nicholls DP Br J Clin Pharmacol; 1990 May; 29(5):519-24. PubMed ID: 2112405 [TBL] [Abstract][Full Text] [Related]
6. Failure of "effective" treatment for heart failure to improve normal customary activity. Walsh JT; Andrews R; Evans A; Cowley AJ Br Heart J; 1995 Oct; 74(4):373-6. PubMed ID: 7488449 [TBL] [Abstract][Full Text] [Related]
7. Effect of flosequinan on exercise capacity and symptoms in severe heart failure. Elborn JS; Stanford CF; Nicholls DP Br Heart J; 1989 Apr; 61(4):331-5. PubMed ID: 2653391 [TBL] [Abstract][Full Text] [Related]
8. Flosequinan in chronic heart failure: how is exercise capacity improved? Banning AP; Ramsey MW; Jones EA; Evans W; Carolan G; Jones CH; Henderson AH Eur J Clin Pharmacol; 1996; 51(2):133-8. PubMed ID: 8911877 [TBL] [Abstract][Full Text] [Related]
9. Acute and chronic effects of flosequinan on resting and exercise haemodynamics in congestive heart failure. Thomas P; O'Gorman DJ; Sheridan DJ Br J Clin Pharmacol; 1993 Dec; 36(6):539-46. PubMed ID: 12959270 [TBL] [Abstract][Full Text] [Related]
10. Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects. Cowley AJ; Wynne RD; Stainer K; Fullwood L; Rowley JM; Hampton JR BMJ; 1988 Jul; 297(6642):169-73. PubMed ID: 3044507 [TBL] [Abstract][Full Text] [Related]
11. A double-blind, parallel-group comparison of flosequinan and enalapril in the treatment of chronic heart failure. Silke B; Tennet H; Fischer-Hansen J; Keller N; Heikkila J; Salminen K Eur Heart J; 1992 Aug; 13(8):1092-100. PubMed ID: 1505560 [TBL] [Abstract][Full Text] [Related]
12. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. Packer M; Narahara KA; Elkayam U; Sullivan JM; Pearle DL; Massie BM; Creager MA J Am Coll Cardiol; 1993 Jul; 22(1):65-72. PubMed ID: 8509565 [TBL] [Abstract][Full Text] [Related]
13. Effects of enoximone in patients with heart failure uncontrolled by captopril and diuretics. Cowley AJ; Stainer K; Fullwood L; Muller AF; Hampton JR Int J Cardiol; 1990 Jul; 28 Suppl 1():S45-52; discussion 52-3. PubMed ID: 2145238 [TBL] [Abstract][Full Text] [Related]
15. Acute and long-term effects of flosequinan in patients with chronic cardiac failure. Marchionni N; Moschi G; Di Bari M; Burgisser C; Fumagalli S; Boncinelli L; Tarantini F; Ferrucci L Am Heart J; 1993 Jul; 126(1):147-54. PubMed ID: 8322657 [TBL] [Abstract][Full Text] [Related]
16. Value of the Bruce protocol to determine peak exercise oxygen consumption in patients evaluated for cardiac transplantation. Strzelczyk TA; Cusick DA; Pfeifer PB; Bondmass MD; Quigg RJ Am Heart J; 2001 Sep; 142(3):466-75. PubMed ID: 11526360 [TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of flosequinan in heart failure. Cowley AJ Am Heart J; 1991 Mar; 121(3 Pt 1):983-8. PubMed ID: 2000777 [TBL] [Abstract][Full Text] [Related]
18. A non-invasive evaluation of flosequinan on haemodynamics and exercise capacity in chronic congestive heart failure. Motro M; Freimark D; Feinberg MS; Wynne RD; King C; Schneeweiss A Int J Clin Pharmacol Res; 1993; 13(3):143-9. PubMed ID: 8225697 [TBL] [Abstract][Full Text] [Related]
19. Assessing exercise capacity, quality of life and haemodynamics in heart failure: do the tests tell us the same thing? Houghton AR; Harrison M; Cowley AJ; Hampton JR Eur J Heart Fail; 2002 Jun; 4(3):289-95. PubMed ID: 12034154 [TBL] [Abstract][Full Text] [Related]
20. A comparison of the effects of flosequinan, a new vasodilator, and propranolol on sub-maximal exercise in healthy volunteers. Lewis HM; Kendall MJ; Smith SR; Bratty JR Br J Clin Pharmacol; 1989 May; 27(5):547-52. PubMed ID: 2757879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]